Recaps progress made in 2020 notwithstanding the ongoing COVID-19 pandemic and previews anticipated 2021 milestones LYON, France , January 6, 2021 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy-based therapies, today issued the following letter to shareholders:

Results on 3,329 patients demonstrate significant difference in efficacy in favor of HIFU versus Radical Prostatectomy (RP) HIFU treatment also resulted in meaningful benefits in both urinary and erectile function versus RP showing superior quality of life preservation capability LYON, France ,

  LYON, France , January 19, 2021 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy based therapies, today announced that Marc Oczachowski , President and CEO, will participate in a fireside chat at the B. Riley Securities Virtual Oncology Investor Conference on

  Record HIFU revenue growth of 50% in the fourth quarter 2020 driven by the sale of eight HIFU devices sold during the quarter Achieved sequential quarterly revenue growth throughout 2020 notwithstanding challenges posed by the ongoing COVID-19 pandemic Company to announce fourth quarter and full

  Initiatives focused on making HIFU procedures broadly accessible to both Medicare and commercially insured patients  LYON, France , March 3, 2021 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy-based therapies, announces today that the company has selected

Company to host conference call and webcast on Wednesday, March 31 at 8:30 am EDT LYON, France , March 23, 2020 - EDAP TMS SA (Nasdaq: EDAP), the global leader in robotic energy-based therapies, today announced that it will release its financial results for the fourth quarter and year ended

Generated record fourth quarter revenue of EUR 15.4 million ( USD 18.3 million ), an increase of 28% year-over-year; HIFU revenue up 51% year-over-year Generated €41.7 million revenue and profitable operating result for the full year 2020. Completed sales to renowned healthcare institutions, such

LYON, France, April 22, 2021 -- EDAP TMS S.A. (NASDAQ: EDAP) (the “Company”), a global leader in robotic energy-based therapies, announced today the launch of a follow-on public offering of its American Depositary Shares, or ADSs, each representing one ordinary share of the Company.

LYON, France, April 23, 2021 -- EDAP TMS S.A. (NASDAQ: EDAP) (the “Company”), a global leader in robotic energy-based therapies, announced that the price of its offering of American Depositary Shares (“ADS”) has been set at $6.75 per ADS and that the number of offered ADSs is 4,150,000 for an

Company to host conference call and webcast on Wednesday , May 12 at 8:30 am EDT LYON, France, May 4 , 20 2 1 - EDAP TMS SA (Nasdaq: EDAP), a global leader in robotic energy-based therapies, today announced that it will release its financial results for the first quarter ended March 31, 2021 after